Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.
Berman
Brian
B
University of Colorado School of Medicine, Denver, Colorado, USA.
Seeberger
Lauren
L
Kumar
Rajeev
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000009:adverse effects; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D013995:Time; D014103:Torticollis / Q000188:drug therapy*; D016896:Treatment Outcome
D018726:Anti-Dyskinesia Agents; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A